MLS Medical Solutn

Medical Solutions PLC
18 October 2007

                                        For further information, please contact:
                                                           Medical Solutions plc
                                                                        Nick Ash
                                                               Managing Director
                                                              Tel: 0115 973 9010
                                                     www.medical-solutions.co.uk

                                                  Bishopsgate Communications Ltd
                                                          Nick Rome/Sophie Davis
                                                               Tel: 0207 5623350
                                               www.bishopsgatecommunications.com


18 October 2007

                             Medical Solutions plc

                             ('Medical Solutions')

          Medical Solutions wins LBC agreement in Jersey worth #150,000

The Board of Medical Solutions plc (LSE: MLS), the provider of expert, quality
services and products to the healthcare, pharma biotech and life sciences
research sectors is pleased to announce that Jersey NHS Trust has chosen the
SurePath(TM)liquid based cytology (LBC) system for their cervical screening
programme.

The Jersey NHS Trust has signed a three year agreement with Medical Solutions
for the provision of the SurePath(TM)system worth approximately #150,000 in
total. Training with the Trust will commence in November and roll out will be
rapid thereafter.

Medical Solutions has previously reported the completion of the planned SurePath
(TM)LBC system roll out programme in England and Wales, consolidating an
estimated 47% of the market share for England and Wales.



                                    --ENDS--



About Medical Solutions

Medical Solutions is a leading provider of expert, quality services and products
to the healthcare, pharma biotech and life science research sectors.  Its
Healthcare operations provide screening products and reference laboratory
diagnostic testing services for cancer and other diseases and additional
predictive testing for treatment optimisation for clinicians and patients.
Pharma Biotech Services offers support for early stage therapeutic development,
offering a "one-stop shop" from tissue pathology, immunohistochemistry,
sophisticated image analysis, biomarker determination and assay development to
pharmacogenomics including genotyping and gene expression analysis.  The Life
Science Research services provide core laboratory research support from
conceptualization to implementation, calling upon a wide ranging of cutting-edge
technology platforms including and an online catalogue of biomolecular tools.
This incorporates DNA sequencing, whole genome amplification and a comprehensive
library of genomic reagents and clones including cDNA and RNAi.

The group has its headquarters in Nottingham, UK where it operates state of the
art reference laboratory facilities, with additional UK laboratory facilities in
Cambridge and Oxford.   Medical Solutions is CPA and GLP accredited and is
licensed by the Human Tissue Authority.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END

NRAILFITILLDLID

Medical Solutions (LSE:MLS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Medical Solutions (LSE:MLS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024